Iron Deficiency: Managed Care Considerations for Optimizing Use of IV Iron Replacement Therapies

Iron deficiency is often associated with chronic diseases, such as heart failure (HF), chronic kidney disease (CKD), and inflammatory bowel disease (IBD). This educational activity will review the role of IV iron replacement in iron deficiency and accompanying chronic conditions and focus on the economic burden of these diseases and the impact of IV iron on healthcare resource utilization.


6:30- 6:35 PM-  Welcome and Opening Remarks
6:35- 6:45 PM-  Overview of Iron Deficiency
6:45- 7:20 PM-  IV Iron Replacement Therapies and Latest Clinical Evidence on Efficacy, Safety, and Impact on Comorbidities
7:20- 7:40 PM-  Managed Care Strategies for Optimizing Evidence-Based and Cost-Effective Use
7:40-8:00 PM-   Question and Answer Session 


Date / Time
Event Details


YuQian Liu, PharmD

Senior Director, Specialty Clinical Solutions
Magellan Rx Management
Middletown, RI

Branden D. Nemecek, PharmD, BCPS

Associate Professor
Pharmacy Practice
Duquesne University
Clinical Pharmacist
University of Pittsburgh Medical Center Mercy Hospital
Pittsburgh, Pennsylvania

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners about optimizing evidence-based and cost-effective use of IV iron replacement therapies.

Target Audience
This activity is intended for pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with iron deficiency, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Recognize the etiology, pathophysiology, and impact of iron deficiency in common comorbidities such as HF, CKD, and IBD
  • Discuss efficacy and safety data regarding IV iron replacement therapies for the treatment of iron deficiency in concomitant chronic conditions, as well as recommended dosing and appropriate implementation of these agents
  • Determine strategies to optimize access to appropriate patient-centered therapies and mitigate financial burdens to improve the management of iron deficiency and promote efficient healthcare resource utilization


Continuing Pharmacy Education

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-203-L01-P has been assigned to this live application-based activity (initial release date 10/13/2022). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at at, and proof of completion will be posted in NABP CPE Monitor profiles.

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.